» Articles » PMID: 10579119

Interleukin-10 Gene-deficient Mice Develop a Primary Intestinal Permeability Defect in Response to Enteric Microflora

Overview
Specialty Gastroenterology
Date 1999 Dec 1
PMID 10579119
Citations 134
Authors
Affiliations
Soon will be listed here.
Abstract

The normal intestinal epithelium provides a barrier relatively impermeable to luminal constituents. However, patients with inflammatory bowel disease experience enhanced intestinal permeability that correlates with the degree of injury. IL-10 gene-deficient mice were studied to determine whether increased intestinal permeability occurs as a primary defect before the onset of mucosal inflammation or is secondary to mucosal injury. At 2 weeks of age, IL-10 gene-deficient mice show an increase in ileal and colonic permeability in the absence of any histological injury. This primary permeability defect is associated with increased mucosal secretion of interferon-gamma and tumor necrosis factor-alpha, and does not involve an increase in nitric oxide synthase activity. Colonic permeability remains elevated as inflammation progresses, while ileal permeability normalizes by 6 weeks of age. IL-10 gene-deficient mice raised under germ-free conditions have no inflammation, and demonstrate normal permeability and cytokine levels. This data suggests that the intestinal permeability defect in IL-10 gene-deficient mice occurs due to a dysregulated immune response to normal enteric microflora and, furthermore, this permeability defect exists prior to the development of mucosal inflammation.

Citing Articles

Pasteurized Timepie001 ameliorates DSS-induced ulcerative colitis in mice by alleviating intestinal injury and modulating gut microbiota.

Han H, Xiong H, Liu Z, Liu X, Wang H, Kou J Front Microbiol. 2025; 16:1542522.

PMID: 40046294 PMC: 11880272. DOI: 10.3389/fmicb.2025.1542522.


Neisseria gonorrhoeae induces local secretion of IL-10 at the human cervix to promote colonization.

Dai Y, Edwards V, Yu Q, Tettelin H, Stein D, Song W J Clin Invest. 2024; 135(2.

PMID: 39585777 PMC: 11735093. DOI: 10.1172/JCI183331.


Early subclinical stages of the inflammatory bowel diseases: insights from human and animal studies.

Kelly C, Sartor R, Rawls J Am J Physiol Gastrointest Liver Physiol. 2024; 328(1):G17-G31.

PMID: 39499254 PMC: 11901386. DOI: 10.1152/ajpgi.00252.2024.


The epithelial barrier theory and its associated diseases.

Sun N, Ogulur I, Mitamura Y, Yazici D, Pat Y, Bu X Allergy. 2024; 79(12):3192-3237.

PMID: 39370939 PMC: 11657050. DOI: 10.1111/all.16318.


Restore Intestinal Barrier Integrity: An Approach for Inflammatory Bowel Disease Therapy.

Kong C, Yang M, Yue N, Zhang Y, Tian C, Wei D J Inflamm Res. 2024; 17:5389-5413.

PMID: 39161679 PMC: 11330754. DOI: 10.2147/JIR.S470520.